Education
About Us
Working with TipRanks
Follow Us
Implanet SA (FR:ALIMP)
:ALIMP
ALIMP Stock Chart & Stats
€0.26
<€0.01(1.57%)
At close: 4:00 PM EST
€0.26
<€0.01(1.57%)
Day’s Range― - ―
52-Week Range€0.08 - €0.44
Previous CloseN/A
Volume2.90K
Average Volume (3M)332.66K
Market Cap
€32.93M
Enterprise Value€38.55M
Total Cash (Recent Filing)€502.00K
Total Debt (Recent Filing)€6.12M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Feb 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding143,818,970
10 Day Avg. Volume485,065
30 Day Avg. Volume332,657
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)18.30
Price to Sales (P/S)1.41
P/FCF Ratio-4.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product Portfolio & Market FocusImplanet’s focused product set—vertebral fixation systems and orthopedic implants—targets hospitals and surgical centers where demand is structural. Specialization supports durable clinical adoption, clearer R&D priorities, and deeper relationships with surgeons and distributors over the medium term.
Strong Recent Revenue GrowthA ~52% reported revenue growth indicates successful market traction and expanding product uptake. If sustained, this growth can help scale fixed costs, improve bargaining with suppliers and distributors, and create a foundation for improving margins and funding incremental R&D without relying solely on financing.
Improving Gross MarginsImproving gross margin signals better pricing power or lower product costs, which are key to long-term margin sustainability in medical devices. Higher gross margins enable reinvestment in R&D and commercialization, increasing chances of moving toward positive EBIT if maintained alongside revenue growth.
Bears Say
High Leverage And Weak EquityA highly leveraged balance sheet with minimal or negative equity reduces resilience to revenue shocks and increases refinancing risk. Over months, leverage constrains strategic flexibility, raises interest burdens, and can force dilutive financing if operating trends do not rapidly improve.
Persistent Negative Operating And Free Cash FlowOngoing negative OCF and free cash flow indicate the business cannot internally fund operations or growth. Medium-term reliance on external financing exposes the company to capital market cycles, potentially limiting investment in sales, inventory, or R&D and risking liquidity stress if funding tightens.
Consistent Unprofitability At EBIT And Net LevelsSustained negative EBIT and net losses reflect operational challenges and cost structure issues. Without a clear path to sustained profitability, the firm may struggle to generate retained earnings for reinvestment, undermining long-term competitiveness and increasing dependence on external capital.
ALIMP FAQ
What was Implanet SA’s price range in the past 12 months?
Implanet SA lowest stock price was €0.08 and its highest was €0.44 in the past 12 months.
What is Implanet SA’s market cap?
Implanet SA’s market cap is €32.93M.
When is Implanet SA’s upcoming earnings report date?
Implanet SA’s upcoming earnings report date is Feb 24, 2026 which is in 8 days.
How were Implanet SA’s earnings last quarter?
Implanet SA released its earnings results on Sep 16, 2025. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.017.
Is Implanet SA overvalued?
According to Wall Street analysts Implanet SA’s price is currently Overvalued.
Does Implanet SA pay dividends?
Implanet SA does not currently pay dividends.
What is Implanet SA’s EPS estimate?
Implanet SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Implanet SA have?
Implanet SA has 143,818,970 shares outstanding.
What happened to Implanet SA’s price movement after its last earnings report?
Implanet SA reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Implanet SA?
Currently, no hedge funds are holding shares in FR:ALIMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Implanet SA
Implanet SA (ALIMP) is a French medical technology company specializing in the development and commercialization of innovative implants and associated surgical instruments for orthopedic and spinal surgery. The company focuses on providing advanced solutions to enhance patient outcomes and improve surgical efficiency, with a product portfolio that includes vertebral fixation systems and orthopedic implants tailored for various surgical applications.
Technical Analysis
Theraclion SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Euromedis Groupe SA
―
Median Technologies
―